158 related articles for article (PubMed ID: 16175615)
41. New antiviral therapies for hepatitis C.
O'Leary J; Chung RT
Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):265-74. PubMed ID: 14695693
[No Abstract] [Full Text] [Related]
42. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
Meanwell NA; Watkins WJ
J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
[No Abstract] [Full Text] [Related]
43. A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.
Conway JM; Perelson AS
PLoS Comput Biol; 2014 Aug; 10(8):e1003769. PubMed ID: 25101902
[TBL] [Abstract][Full Text] [Related]
44. Advances and challenges in studying hepatitis C virus in its native environment.
Sheahan T; Jones CT; Ploss A
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):541-50. PubMed ID: 20932139
[TBL] [Abstract][Full Text] [Related]
45. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy.
Layden TJ; Layden JE; Ribeiro RM; Perelson AS
Clin Liver Dis; 2003 Feb; 7(1):163-78. PubMed ID: 12691465
[TBL] [Abstract][Full Text] [Related]
46. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Mariño Z; van Bömmel F; Forns X; Berg T
Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
[No Abstract] [Full Text] [Related]
47. Very late HCV relapse following triple therapy for hepatitis C.
Barreiro P; Vispo E; Maida I; Aguilera A; Fernández-Montero JV; de Mendoza C; Labarga P; Soriano V
Antivir Ther; 2014; 19(7):723-4. PubMed ID: 24535551
[No Abstract] [Full Text] [Related]
48. Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements.
Berg T; Pascu M; Möller B
Hepatology; 2003 Jun; 37(6):1495-6; author reply 1496. PubMed ID: 12774030
[No Abstract] [Full Text] [Related]
49. Estimation of dynamical model parameters taking into account undetectable marker values.
Thiébaut R; Guedj J; Jacqmin-Gadda H; Chêne G; Trimoulet P; Neau D; Commenges D
BMC Med Res Methodol; 2006 Aug; 6():38. PubMed ID: 16879756
[TBL] [Abstract][Full Text] [Related]
50. From basic molecular biology to curative antiviral therapy: the success story of Hepatitis C virology.
Reddehase MJ
Med Microbiol Immunol; 2019 Feb; 208(1):1-2. PubMed ID: 30328536
[No Abstract] [Full Text] [Related]
51. ADAP recipients offered free HCV drug therapy. Schering-Plough makes offer to states.
AIDS Alert; 2005 May; 20(5):59-60. PubMed ID: 15912618
[TBL] [Abstract][Full Text] [Related]
52. Miravirsen works against hepatitis C virus.
BMJ; 2013 Apr; 346():f2069. PubMed ID: 23553883
[No Abstract] [Full Text] [Related]
53. Viral kinetic modeling: state of the art.
Canini L; Perelson AS
J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):431-43. PubMed ID: 24961742
[TBL] [Abstract][Full Text] [Related]
54. Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.
Hutchison C; Kwong A; Ray S; Struble K; Swan T; Miller V
Clin Pharmacol Ther; 2014 Aug; 96(2):162-5. PubMed ID: 24853733
[TBL] [Abstract][Full Text] [Related]
55. HCV Eradication: A Duty of the State, an Option for the Individual.
Craxì L
Adv Exp Med Biol; 2020; 1282():85-91. PubMed ID: 31808124
[TBL] [Abstract][Full Text] [Related]
56. A new era in HCV treatment.
Berger DS
Posit Aware; 2011; 23(3):42-3. PubMed ID: 21776910
[No Abstract] [Full Text] [Related]
57. Viral kinetics of hepatitis C: new insights and remaining limitations.
Layden JE; Layden TJ
Hepatology; 2002 Apr; 35(4):967-70. PubMed ID: 11915047
[No Abstract] [Full Text] [Related]
58. Improving patient access to hepatitis C virus treatment.
McLaughlin MM; Marx KT; Terriff C;
J Am Pharm Assoc (2003); 2018; 58(1):109-112.e1. PubMed ID: 29154018
[TBL] [Abstract][Full Text] [Related]
59. Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach.
Laouénan C; Guedj J; Mentré F
BMC Med Res Methodol; 2013 Apr; 13():60. PubMed ID: 23617810
[TBL] [Abstract][Full Text] [Related]
60. Can we use viral kinetic models to individualize treatment?
Guedj J; Nguyen TH
Liver Int; 2015 Feb; 35(2):297-8. PubMed ID: 25394573
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
